ライフサイエンスコーパス: phospholipase A2

1 ry enzymes (ciclooxygenase, lipoxygenase and phospholipase A2).

2 ive oral inhibitor of lipoprotein-associated phospholipase A2.

3 ting Ca(2+) signals that were independent of phospholipase A2.

4 ipid as a novel substrate of honey bee venom phospholipase A2.

5 s also referred to as lipoprotein-associated phospholipase A2.

6 e, secretory sphingomyelinase, and secretory phospholipase A2.

7 ell as HDL remodeling by group IIa secretory phospholipase A2.

8 y a pathway that is independent of group IVa phospholipase A2.

9 PAF-AH2, an oxidized-phospholipid-selective phospholipase A2.

10 ts and reduced the activation of cytoplasmic phospholipase A2.

11 ase D2 and diacylglycerol kinase rather than phospholipase A2.

12 crosis factor-alpha, C-reactive protein, and phospholipase A2.

13 osolic phospholipase A2, calcium-independent phospholipase A2, 12/15 and 5-lipoxygenase) is expressed

14 89+/-8 ng/mL), higher lipoprotein-associated phospholipase A2 (242+/-12 versus 215+/-5 ng/mL), and hi

15 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-L

16 o 0.55, p<0.0001) and lipoprotein-associated phospholipase A2 (-52.2 ng/mL, 95% CI -70.4 to -34.0, vs

17 Neither group IIa phospholipase A2, a close homolog of gVPLA2, nor W31A, a

18 Blocking of phospholipase A2 abrogated C-reactive protein dissociati

19 evels of prostaglandin E2 The non-functional phospholipase A2-activating protein and the associated n

20 a loss of function sequence variation in the phospholipase A2-activating protein encoding gene (PLAA)

21 Reduced Ca(2+)-dependent cytosolic phospholipase A2 activation and oxidative metabolism of

22 ted cell membranes, which is generated after phospholipase A2 activation.

23 induced [Formula: see text] signals required phospholipase A2 activation.

24 se cleavages disrupt both the peroxidase and phospholipase A2 activities of Prdx6.

25 l or Prdx6-D140A-knock-in mice that lack the phospholipase A2 activity (PLA2) of Prdx6; addition of e

26 easurement of prostaglandin E2 and cytosolic phospholipase A2 activity in membrane fractions of fibro

27 ically with ubiquitin to greatly enhance the phospholipase A2 activity of ExoU.

28 The phospholipase A2 activity of peroxiredoxin 6 modulates N

29 Treatment with PEDF activates the phospholipase A2 activity of the PEDF-receptor (PEDF-R)

30 Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vu

31 onses are elicited through lipid products of phospholipase A2 activity that acts on the membrane phos

32 ExoU is a potent cytotoxin with phospholipase A2 activity that causes rapid necrotic dea

33 ly one type of capsid protein that lacks the phospholipase A2 activity that has been implicated as a

34 es to the plasma membrane, where it uses its phospholipase A2 activity to lyse infected cells.

35 th a PPARalpha activator increased secretory phospholipase A2 activity, which likely accounts for acc

36 tics of the payload discharge appeared to be phospholipase A2 activity-dependent, as determined by me

37 hospholipases, which have been shown to have phospholipase A2 activity.

38 r levels of hsCRP and lipoprotein-associated phospholipase A2 after AMI compared with men, and this r

39 doxin 6 (Prdx6), a bifunctional protein with phospholipase A2 (aiPLA2) and GSH peroxidase activities,

40 2+) release from internal stores, activating phospholipase A2 and generating vasodilatory arachidonic

41 Both secretory phospholipase A2 and lipoprotein-associated phospholipas

42 Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipas

43 eding with clinical outcome trials secretory phospholipase A2 and lipoprotein-associated phospholipas

44 ugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a role in the pathogenesis of

45 -arrestin1-dependent activation of cytosolic phospholipase A2 and release of arachidonate, the precur

46 t, by an ATP inhibitor, and by inhibitors of phospholipase-A2 and -C.

47 While phospholipases A2 and C have been recently shown to medi

48 Phospholipases A2 and D had no effect on SHFV entry.

49 serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhydrase 6).

50 ent alpha1G subtype Ca2+ channels, cytosolic phospholipase A2, and epoxyeicosatrienoic acids.

51 embrane phospholipids by group IVA cytosolic phospholipase A2, and its conversion to bioactive lipoxi

52 Tgm2, group 10 secretory phospholipase A2, and LT enzymes in NHBEs and nasal poly

53 cell adhesion molecule 1 (VCAM-1), secretory phospholipase A2, and malondialdehyde and hydroxyalkenal

54 ANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein w

55 ion is the liberation of arachidonic acid by phospholipase A2, and the cytosolic phospholipase A2 (cP

56 Glial TRPV4 signals were phospholipase A2- and cytochrome P450-dependent, charact

57 7-yl)amino)hexyl]-1H-pyrrole-2,5-dion e] and phospholipase A2 (arachidonyltrifluoromethyl ketone).

58 obtained for nonaged complexes of group-VIII phospholipase A2 are compared to those obtained for othe

59 phospholipase A2 and lipoprotein-associated phospholipase A2 are potential candidates for reducing r

60 ing of beta-arrestin1 to activated cytosolic phospholipase A2 as well as beta-arrestin1-dependent act

61 d on a denatured form of the major allergen, phospholipase A2, associated with microbubbles (PLA2dena

62 hetic enzymes includes (1) the activation of phospholipase A2 at the plasma membrane, resulting in a

63 c activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with higher plasma interleu

64 gene encodes a group VIA calcium-independent phospholipase A2 beta enzyme that selectively hydrolyses

65 DX6 or inhibition of its calcium-independent phospholipase A2 (Ca(2+)-iPLA2) activity by MJ33 on fert

66 RvD1 biosynthetic machinery (e.g., cytosolic phospholipase A2, calcium-independent phospholipase A2,

67 at a number of oxygenated CL species undergo phospholipase A2-catalysed hydrolysis and thus generate

68 The lipid modifier phospholipase A2 catalyzes the hydrolysis of phospholipi

69 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, COX-2, multidrug resistance protein 4,

70 nsis-infected macrophages requires cytosolic phospholipase A2 (cPLA(2)), cyclooxygenase 2 (COX-2), an

71 s study was to investigate whether cytosolic phospholipase A2 (cPLA2 ), an important isoform of PLA2

72 ls of MYC, we found an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential re

73 GPIb-IX-induced phosphorylation of cytosolic phospholipase A2 (cPLA2) and consequent thromboxane A2 (

74 gs exist regarding the function of cytosolic phospholipase A2 (cPLA2) and its role in membrane regula

75 ctivates the enzymatic activity of cytosolic phospholipase A2 (cPLA2) as at-tested to by arachidonic

76 the relatively lower expression of cytosolic phospholipase A2 (cPLA2) in H596 cells than that of A549

77 cts the expression and activity of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2), and

78 Tissue damage activates cytosolic phospholipase A2 (cPLA2), releasing arachidonic acid (AA

79 tease-activated receptors 1 and 4, cytosolic phospholipase A2 (cPLA2), Src tyrosine kinases, p38 MAPK

80 AA) from membrane phospholipids by cytosolic phospholipase A2 (cPLA2).

81 acid by phospholipase A2, and the cytosolic phospholipase A2 (cPLA2)alpha isoform has been specifica

82 ics simulation of the C2 domain of cytosolic phospholipase A2 (cPLA2-C2) in a 1-palmitoyl-2-oleoyl-ph

83 The role of Group IVA cytosolic phospholipase A2 (cPLA2alpha) activation in regulating m

84 Group IVA cytosolic phospholipase A2 (cPLA2alpha) acts as a bridge in this c

85 hown to require activation of host cytosolic phospholipase A2 (cPLA2alpha) by Loops1 and 2 but not 3.

86 fter pharmacological inhibition of Group IVA phospholipase A2 (cPLA2alpha) or down-regulation of cera

87 compelling evidence that group IVA cytosolic phospholipase A2 (cPLA2alpha) targets arachidonic acid-c

88 es through activation of group IVA cytosolic phospholipase A2 (cPLA2alpha).

89 -of-function mutation in group IVA cytosolic phospholipase A2 (cPLA2alpha).

90 crophages, activation of group IVA cytosolic phospholipase A2(cPLA2alpha) by calcium- and mitogen-act

91 Cytosolic phospholipases A2 (cPLA2s) consist of a family of calciu

92 The inhibition of phospholipase A2, cyclooxygenase, or blockade of the thr

93 E2 (PGE2) via a calcium-dependent cytosolic phospholipase A2/cyclooxygenase-mediated mechanism.

94 Group IVA phospholipase A2 [cytosolic phospholipase A2alpha (cPLA2

95 at localizes and aggravates inflammation via phospholipase A2-dependent dissociation of circulating p

96 and free fatty acid content and a cytosolic phospholipase A2-dependent increase in formation of lipi

97 xperiments confirmed ANXA1 as an independent phospholipase A2-dependent monocyte recruiter; congruent

98 B. p67(phox) terminates the phospholipase A2-derived signal for activation of NADPH

99 The importance of the phospholipase A2 domain located within the unique N term

100 ly when T3SS-positive bacteria expressed the phospholipase A2 effector Exotoxin U (ExoU).

101 ExoU is a potent phospholipase A2 effector protein secreted by the type I

102 In contrast, the levels of phospholipase A2, enkephalin, PSD-95, synaptophysin, or

103 Phospholipase A2 enzymes are ubiquitously distributed th

104 We studied the expression of multiple phospholipase A2 enzymes in human macrophages and the ef

105 hogens have acquired genes encoding secreted phospholipase A2 enzymes through lateral gene transfer e

106 Finally, phosphorylated-phospholipase A2 expression was significantly higher in

107 phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enzymes, produced predominant

108 We have documented the expression of the phospholipase A2 family of genes in aortic valves by usi

109 Because these cells contain multiple phospholipase A2 forms, the challenge is to elucidate th

110 on, soman, and sarin complexes of group-VIII phospholipase A2 from bovine brain.

111 urons caused the dissociation of cytoplasmic phospholipase A2 from PrP-containing membrane rafts and

112 hich may (i) release VP1 amino acids for its phospholipase A2 function for endosomal escape and nucle

113 Phospholipase A2s generate lipid mediators that constitu

114 At least 11 phospholipase A2 genes were found at significant levels

115 The Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is a key provider of subst

116 Cytosolic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhi

117 Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is the rate-limiting provi

118 Here we identify epithelial-cell-derived phospholipase A2 group 1B (PLA2g1B) as a host-derived en

119 tion significantly impairs the expression of phospholipase A2 group 7 (Pla2g7) in macrophages, which

120 ically engineered mice lacking expression of phospholipase A2 group 7 (PLA2G7), an enzyme that specif

121 Secretory phospholipase A2 group IIa (PLA2g2a) is associated with

122 Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identifi

123 Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an importan

124 Eicosanoids, derived from the cytosolic phospholipase A2 group IVA (cPLA2alpha) activation, are

125 A-->G variant (rs12746200) of the cytosolic phospholipase A2 group IVA gene (PLA2G4A), which encodes

126 (INAD), most commonly caused by mutations of phospholipase A2 group VI gene (PLA2G6), but alleles of

127 04, n >/=5/group) for five other NBIA genes, phospholipase A2 group VI, fatty acid 2-hydroxylase, cer

128 Secreted phospholipase A2 group X (sPLA2-X) plays a key role in r

129 t Pla2g5-null mice lacking group V secretory phospholipase A2 (gV-sPLA2) showed reduced eosinophilic

130 We investigated the role of group V phospholipase A2 (gVPLA2) in OVA-induced inflammatory ce

131 Group X secretory phospholipase A2 (GX sPLA2) hydrolyzes mammalian cell me

132 Group X secretory phospholipase A2 (GX sPLA2) potently hydrolyzes membrane

133 Human group IIA secreted phospholipase A2 (hGIIA) promotes tumor growth and infla

134 ipoproteins AI and B, lipoprotein-associated phospholipase A2, homocysteine or folate, some with larg

135 In particular, phospholipase A2 homologues appear to play an important

136 (PUFAs) are released following activation of phospholipase A2, if they are in the diet prior to ischa

137 usly demonstrated up-regulation of secretory phospholipase A2 IIA (sPLA2 IIA) mRNA and protein expres

138 drion is an endogenous substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherw

139 d through the concerted activity of secreted phospholipase A2 IIA (sPLA2-IIA), present in inflammator

140 ense oligonucleotides (one against secretory phospholipase A2 IIa and the other against cytosolic pho

141 red remodeling of HDL by group IIa secretory phospholipase A2 in concert with cholesterol ester trans

142 phospholipase A2 and lipoprotein-associated phospholipase A2 inhibition.

143 In contrast, a specific cytosolic phospholipase A2 inhibitor blocked the oxidant productio

144 Cells treated with the cytosolic phospholipase A2 inhibitor, cPLA2alpha, had no effect on

145 phospholipase A2 and lipoprotein-associated phospholipase A2 inhibitors hold promise for the reducti

146 des the rationale for the development of the phospholipase A2 inhibitors varespladib methyl and darap

147 exposure to fatty acid-free BSA or cytosolic phospholipase A2 inhibitors.

148 igation of this novel lipoprotein-associated phospholipase A2 inhibitory mechanism for the treatment

149 which encodes group VIA calcium-independent phospholipase A2 (iPLA(2)beta), were recently identified

150 influx factor (CIF) and calcium-independent phospholipase A2 (iPLA2) in activation of Ca2+ release-a

151 ntify roles of rab6a and calcium-independent phospholipase A2 (iPLA2) in Golgi enzyme recycling, and

152 Group VIA phospholipase A2 (iPLA2beta) affects beta-cell sensitivi

153 Activation of group VIA phospholipase A2 (iPLA2beta) causes accumulation of arac

154 acrophages, the Ca(2+)-independent group VIA phospholipase A2 (iPLA2beta) has not been clearly define

155 Here we demonstrate that group VIA phospholipase A2 (iPLA2beta) plays a pivotal role in Ang

156 inhibition of the group VIA Ca2+-independent phospholipase A2 (iPLA2beta), associated with an increas

157 One of these, a phospholipase A2 isoenzyme, is capable of releasing a nu

158 idylcholine (Lyso-PC) by activating multiple phospholipase A2 isoforms via CD36.

159 response to barrier disruption of secretory phospholipase A2 isoforms, enzymes that mediate generati

160 Lipoprotein-associated phospholipase A2 levels in the second, third, and fourth

161 s and amphipathic UC from the bilayer to the phospholipase A2-like and esterification active sites of

162 of a heteromeric complex between Kunitz- and phospholipase-A2-like proteins that together function as

163 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key

164 pase A2 (sPLA(2)) and lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are enzyme biomarkers of in

165 vated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovas

166 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be i

167 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-densi

168 regarding the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerosis, partly be

169 presence and role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve dise

170 PPARgamma agonists or lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors may play a role in

171 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and partici

172 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary

173 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of c

174 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the risk o

175 10% reduction in the lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin

176 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coron

177 tients that increased lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associate

178 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipas

179 )-VI isoform), plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL

180 ascular inflammation (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

181 Lysosomal phospholipase A2 (LPLA2) and lecithin:cholesterol acyltr

182 Lysosomal phospholipase A2 (LPLA2, group XV phospholipase A2) resi

183 ive protein (CRP) and lipoprotein-associated phospholipase A2 (LpPLA2).

184 esterol, adiponectin, lipoprotein-associated phospholipase A2 mass and activity, monocyte chemoattrac

185 I, lipoprotein(a), or lipoprotein-associated phospholipase A2 mass to risk scores containing total ch

186 protein(a), 4.1%; and lipoprotein-associated phospholipase A2 mass, 2.7% of people to a 20% or higher

187 I, 0.0010-0.0026) for lipoprotein-associated phospholipase A2 mass.

188 Finally, we propose that cytosolic phospholipase A2 may be a potential source of these hydr

189 arly serum amyloid A and group IIa secretory phospholipase A2, may alter reverse cholesterol transpor

190 Phospholipase A2s mediate the rate-limiting step in the

191 correlated with altered COX-2 and cytosolic phospholipase A2 messenger RNA levels in the joints of C

192 Moreover, the phospholipase A2 motif in the VP1 unique region was also

193 iated with changes in lipoprotein-associated phospholipase A2 (n = 10; r = 0.67; P = .03).

194 on could be detected using phospholipase A1, phospholipase A2, or phospholipase C, allowing for a rel

195 ional enzyme with glutathione peroxidase and phospholipase A2 (PLA(2)) activities, participates in th

196 ls specific for the major bee venom allergen phospholipase A2 (PLA) were isolated from beekeepers who

197 Phospholipase A2 (PLA)-specific B cells were identified

198 ined by demonstrating that bee venom-derived phospholipase A2 (PLA2) activates T cells through genera

199 Phospholipase A2 (PLA2) activity has been shown to be in

200 rfaces of these capsids and maintained their phospholipase A2 (PLA2) activity, as determined by nativ

201 While some patatin-like proteins have phospholipase A2 (PLA2) activity, recombinant TgPL1 puri

202 ybean seeds and positively characterised for phospholipase A2 (PLA2) activity, suggesting their plaus

203 tical methods have been developed to monitor phospholipase A2 (PLA2) activity.

204 Here, we propose that 2 enzymes-phospholipase A2 (PLA2) and ectonucleotide pyrophophatas

205 We investigated the role of phospholipase A2 (PLA2) and the effects of PLA2 products

206 In both plants, an elicitor-responsive phospholipase A2 (PLA2) at the plasma membrane generates

207 ond premicellar complex of pig pancreatic IB phospholipase A2 (PLA2) can be considered a proxy for in

208 the demonstration that lipid enzymes such as phospholipase A2 (PLA2) contain allosteric activator sit

209 teract with and activate the enzyme group-IB phospholipase A2 (PLA2) derived from the pancreas.

210 Phospholipase A2 (PLA2) enzymes act at the membrane-wate

211 Phospholipase A2 (PLA2) enzymes, which catalyze the hydr

212 The mechanisms by which secretory phospholipase A2 (PLA2) exerts cellular effects are not

213 PURPOSE OF REVIEW: The phospholipase A2 (PLA2) family of proteins includes lipo

214 ployed to quantify the catalytic activity of phospholipase A2 (PLA2) in both pure and complex biologi

215 ts were pretreated (i.c.v) with mepacrine [a phospholipase A2 (PLA2) inhibitor], ibuprofen [a nonsele

216 Phospholipase A2 (PLA2) is a conserved component of veno

217 In addition, phospholipase A2 (PLA2) is highly expressed in psoriatic

218 The development of inhibitors for phospholipase A2 (PLA2) is important in elucidating the

219 A phospholipase A2 (PLA2) is thought to be involved in the

220 s are important vascular regulators, but the phospholipase A2 (PLA2) isoforms supporting their produc

221 Intracellular phospholipase A2 (PLA2) plays an important role in regul

222 n after lung challenge with S. pneumoniae As phospholipase A2 (PLA2) promotes the release of AA, we i

223 of cancer cells was critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids an

224 to evaluate the activity of Ca(2+)-dependent phospholipase A2 (PLA2), an inflammatory protein that (i

225 MAPK (mitogen-activated protein kinase) and phospholipase A2 (PLA2), but its action is independent o

226 at are involved in the inflammatory process: phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2), throm

227 le of sequestering and neutralizing venomous phospholipase A2 (PLA2), we demonstrate that broad-spect

228 that gossypol rapidly increased activity of phospholipase A2 (PLA2), which led to an increase in cyt

229 hate (cAMP) and a subsequent inactivation of phospholipase A2 (PLA2), whose metabolites are known to

230 Phospholipase A2 (PLA2)-catalyzed hydrolysis at the sn-2

231 Phospholipase A2 (PLA2)-dependent pathways are important

232 Among snakes, phospholipase A2 (PLA2)-related toxins have evolved in d

233 The phospholipase A2 (PLA2)activity of phosphorylated peroxi

234 Phospholipases A2 (PLA2) catalyze the hydrolysis reactio

235 Phospholipases A2 (PLA2) comprise a superfamily of enzym

236 ), two in apolipoprotein B (APOB) and one in phospholipase A2 (PLA2G4A) that significantly associated

237 eractions between the promoters of COX-2 and phospholipase A2 (PLA2G4A), an adjacent pro-inflammatory

238 l. (2017) provide intriguing evidence that a phospholipase A2 (Pla2gb1) produced by epithelial cells

239 The M-type receptor for phospholipase A2 (PLA2R1) is the major target antigen in

240 is study, we assessed the role of macrophage phospholipases A2 (PLA2s) in defense against M. tubercul

241 rlying this dysfunction, we demonstrate that phospholipases A2 (PLA2s), namely the cytosolic and the

242 oop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-bind

243 tment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies an

244 The phospholipase A2 receptor (PLA2R) and thrombospondin typ

245 The characterization of the phospholipase A2 receptor (PLA2R) as the major target an

246 Phospholipase A2 receptor (PLA2R) is a member of the man

247 The M-type phospholipase A2 receptor (PLA2R) is expressed in podocy

248 Secretory phospholipase A2 receptor (PLA2R) is the target antigen

249 We sought to determine the utility of phospholipase A2 receptor (PLA2R) staining for the detec

250 complement-fixing IgG4 autoantibodies to the phospholipase A2 receptor (PLA2R).

251 pathy (IMN) have IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

252 wed that genetic variants in an HLA-DQA1 and phospholipase A2 receptor (PLA2R1) allele associate most

253 The phospholipase A2 receptor (PLA2R1) is the major autoanti

254 The phospholipase A2 receptor (PLA2R1) is the major autoanti

255 le is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein

256 is known about the physiological role of the phospholipase A2 receptor (PLA2R1).

257 tly discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin t

258 Phospholipase A2 receptor 1 (PLA2R) is a target autoanti

259 very of the major target antigen, the M-type phospholipase A2 receptor 1 (PLA2R).

260 bodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently id

261 s associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1).

262 ephropathy (MN) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

263 01) per gram, P = 0.010] and those with anti-phospholipase A2 receptor antibodies [hazard ratio = 3.7

264 ptor (FcRY) is the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family mem

265 culating autoantibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of gl

266 Lysosomal phospholipase A2 (LPLA2, group XV phospholipase A2) resides in the endocytic system, the m

267 e ExoU type III secretion enzyme is a potent phospholipase A2 secreted by the Gram-negative opportuni

268 Phospholipase A2-specific IgG4-switched memory B cells e

269 Secretory phospholipase A2 (sPLA(2)) and lipoprotein-associated ph

270 The group IIA secretory phospholipase A2 (sPLA(2)-IIA) has been studied extensiv

271 , LTE4 , PGD2 , and PGE2 , plasma secretory phospholipase A2 (sPLA2 ), and 11beta prostaglandin F2al

272 Group IB secretory phospholipase A2 (sPLA2 IB), which is one of the ligands

273 Observational studies report that secretory phospholipase A2 (sPLA2) activity is a marker for corona

274 Paneth cell antimicrobial molecule secretory phospholipase A2 (sPLA2) and the goblet cell glycoprotei

275 Secretory phospholipase A2 (sPLA2) enzymes are considered to play

276 Secretory phospholipase A2 (sPLA2) generates bioactive phospholipi

277 hase of the inflammatory response, secretory phospholipase A2 (sPLA2) reaches its maximum levels in p

278 ays, we found expression levels of secretory phospholipase A2 (sPLA2), lysophospholipid acyltransfera

279 sought to investigate the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease.

280 tional screen, we have identified a secreted phospholipase A2 (sPLA2)-like protein, BomoTx, from the

281 ural rigidity in the inhibition of secretary phospholipase A2 (sPLA2).

282 The type IIA secretory phospholipase A2 (sPLA2-IIA) is a host protein endowed w

283 analyze the role of human group IIA secreted phospholipase A2 (sPLA2-IIA), a bactericidal enzyme indu

284 strong upregulation of the secreted group V phospholipase A2 (sPLA2-V), both at the mRNA and protein

285 Secreted phospholipases A2 (sPLA2's) are enzymes that hydrolyze g

286 Here, we identify secreted phospholipases A2 (sPLA2s) as stem cell niche factors wi

287 We report a series of inhibitors of secreted phospholipases A2 (sPLA2s) based on substituted indoles,

288 We have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit th

289 ity to induce prostaglandin E2 and cytosolic phospholipase A2 synthesis in patients' fibroblasts.

290 ivating factor acetylhydrolase (PAF-AH) is a phospholipase A2 that inactivates potent lipid messenger

291 stence in two evolutionary distant plants of phospholipases A2 that discriminate "self-made" from "fo

292 of the phospholipids are removed from CcO by phospholipase A2 (the half-life decreases at 37 degrees

293 d a novel cardiolipin hydrolysis reaction by phospholipase A2 to form diacylated cardiolipin progress

294 on, the use of phospholipases, in particular phospholipase A2, was essential to define the fatty acid

295 e protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1 month after AMI.

296 fungitoxic metabolites through the action of phospholipase A2, which is enhanced in bacterized plants

297 kinase-dependent activation of the cytosolic phospholipase A2, which releases arachidonic acid from m

298 yclooxygenase-2 and phosphorylated cytosolic phospholipase A2, which was reflected in prostaglandin E

299 mediated activation of a calcium independent phospholipase A2 with resultant synthesis of lysophospha

300 adult mice expressed more group 10 secretory phospholipase A2, Wnt5a, and transglutaminase 2 (Tgm2).